Application of FGL1 protein in preparing a kit for diagnosing eczema or urticaria

By measuring the FGL1 protein content in serum and combining ROC curve and logistic regression analysis, a kit for eczema and urticaria was developed, which solved the problem of lack of objectivity in the diagnosis in the prior art and achieved a high-accuracy diagnostic effect .

CN118566509BActive Publication Date: 2024-11-05JIANGSU PRECISE MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311307434.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-10
Publication Date
2024-11-05
Estimated Expiration
2043-10-10

AI Technical Summary

Technical Problem

The prior art lacks objectivity in the diagnosis of eczema and urticaria, and it is difficult to effectively distinguish healthy individuals and patients.

Method used

Using FGL1 protein as a diagnostic marker, the content of FGL1 protein in serum was determined by ELISA kit, combined with ROC curve and logistic regression analysis, a kit for diagnosing eczema or urticaria was developed.

Benefits of technology

It significantly improves the diagnostic accuracy of eczema and urticaria, can effectively distinguish between healthy subjects and patients, improves the objectivity of the diagnosis, and the accuracy rate reaches 87.10% and 96.67%.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118566509B_ABST
    Figure CN118566509B_ABST
Patent Text Reader

Abstract

The present invention discloses an application of FGL1 protein in preparing a kit for diagnosing eczema or urticaria. The present invention finds that there is a significant difference in the FGL1 protein content in the serum of healthy subjects and patients with eczema or urticaria, and the FGL1 protein content in the serum of patients with eczema or urticaria is significantly higher than that of healthy subjects. Further diagnostic efficacy tests show that FGL1 protein can effectively diagnose and distinguish between healthy subjects and eczema or between healthy subjects and urticaria patients, with a high diagnostic accuracy, and can be used to develop a kit for diagnosing eczema or urticaria to improve diagnostic objectivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of disease diagnosis, relates to the discovery and application of disease diagnosis markers, and specifically relates to the application of FGL1 protein in the preparation of a kit for diagnosing eczema or urticaria. Background Art

[0002] Eczema is a common inflammatory skin disease of the epidermis and superficial dermis caused by a variety of internal and external factors. It is generally believed to be related to allergic reactions. It can occur at any age, in any part of the body, and in any season, but often recurs or worsens in winter. It has a tendency to exudate, a chronic course, and is prone to recurrence.

[0003] Urticaria, commonly known as wheals and hives, is a common allergic disease of the skin and mucous membranes. It is mainly caused by localized edema due to temporary increase in vascular permeability of the skin and mucous membranes. The wheals may be accompanied by obvious severe itching and scratching. The rash of this disease is similar to the skin damage caused by contact with the plant nettle, so it is called urticaria. Urticaria is a global disease with no racial differences. It can occur at any age, and the incidence is affected by environmental factors.

[0004] The present invention is proposed to improve the objectivity of diagnosis of eczema and urticaria. Summary of the invention

[0005] The purpose of the present invention is to overcome the deficiencies of the prior art and provide an application of FGL1 protein in the preparation of a kit for diagnosing eczema or urticaria.

[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0007] A use of FGL1 protein in preparing a kit for diagnosing eczema or urticaria.

[0008] Preferably, the kit is a serum detection kit.

[0009] Preferably, the kit contains a detection reagent for FGL1 protein.

[0010] Beneficial effects:

[0011] The present invention found that there was a significant difference in the FGL1 protein content in the serum of healthy subjects and patients with eczema and urticaria, and the FGL1 protein content in the serum of patients with eczema and urticaria was significantly higher than that of healthy subjects. Further diagnostic efficacy tests showed that the FGL1 protein can effectively diagnose and distinguish between healthy subjects and eczema or diagnose and distinguish between healthy subjects and urticaria patients, with a high diagnostic accuracy, and can be used to develop a kit for diagnosing eczema or urticaria to improve diagnostic objectivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 ROC curve for distinguishing healthy subjects from eczema patients in the training set for FGL1 protein diagnosis;

[0013] Figure 2 This is the sample distribution diagram of healthy subjects vs eczema patients predicted based on FGL1 protein in the validation set;

[0014] Figure 3 ROC curve for distinguishing healthy subjects from urticaria patients in the training set for FGL1 protein diagnosis;

[0015] Figure 4 This is the sample distribution diagram for predicting healthy subjects vs urticaria patients based on FGL1 protein in the validation set. DETAILED DESCRIPTION

[0016] The essential contents of the present invention are described in detail below in conjunction with the embodiments, but the protection scope of the present invention is not limited thereto.

[0017] Example 1: Diagnosis of eczema

[0018] 1. Experimental samples and reagents

[0019] Thirty-one healthy subjects and 20 patients with eczema were collected. Healthy subjects were normal people with healthy physical examinations, and patients with eczema were diagnosed according to the 2021 Chinese Hand Eczema Diagnosis and Treatment Expert Consensus. The two groups of patients were matched in age, gender, and body mass index, with no significant differences. The subjects and patients were randomly divided into training set samples (10 healthy subjects and 10 patients with eczema) and validation set samples (21 healthy subjects and 10 patients with eczema).

[0020] Exclusion criteria:

[0021] ① Patients with other acute diseases or uncontrolled chronic diseases; ② Patients with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system; ③ Patients with mental illness and unable to cooperate; ④ Pregnant or lactating women, or those preparing for pregnancy; ⑤ Those who have participated in other clinical trials within the past month; ⑥ Those who are unwilling to accept this study.

[0022] Main experimental reagents:

[0023] The ELISA reagent for measuring FGL1 protein was purchased from RayBiotech., Inc.

[0024] 2. Experimental Methods

[0025] 1. Collection and storage of serum samples

[0026] Fasting peripheral blood was collected from healthy subjects and eczema patients in the morning and placed in a test tube without anticoagulant. The blood was naturally coagulated for 30-60 minutes at room temperature. After the blood coagulated, it was centrifuged at 2000 rpm for 10 minutes. The upper clear serum liquid was carefully aspirated into a sterile lyophilized tube, labeled, and stored in a -80°C refrigerator for later use.

[0027] 2. ELISA determination of FGL1 protein content in serum

[0028] The content of FGL1 protein in each serum sample was determined strictly according to the ELISA reagent assay instructions.

[0029] 3. Data processing method

[0030] The ROC curve of FGL1 protein in the test set for distinguishing healthy subjects from patients with eczema was established, and the area under the curve (AUC) and 95% confidence interval were calculated. Logistic regression was used to establish a regression equation to generate a set of new variables logit[P]. After logit[P]=Ln [p / (1-p)] The predicted probability p was obtained by transformation, and the ROC curve analysis was performed on the new variable. In the validation set, the diagnostic accuracy of FGL1 for eczema was calculated using the best cut-off value obtained by the ROC curve as the threshold.

[0031] 3. Experimental Results

[0032] 1. Differences in serum levels of FGL1 protein between healthy subjects and patients with eczema

[0033] In the training set, there were significant differences in the levels of FGL1 protein in the serum of healthy subjects VS patients with eczema. The absolute content of FGL1 in the serum of patients with eczema was significantly increased. The measurement results are shown in Table 1.

[0034] Table 1

[0035] Group FGL1 content (ng / mL) eczema 553.74±552.55 Healthy subjects 28.16±16.30

[0036] 2. ROC curve of FGL1 protein diagnosis for distinguishing healthy subjects from eczema patients

[0037] The FGL1 protein content (X) in the training set samples was used as the independent variable, and the group (i.e., healthy subjects and eczema patients) was used as the dependent variable. Logistic regression was performed on the FGL1 protein content in the serum samples of eczema and healthy subjects to obtain the logistic regression equation Ln [p / (1-p)] =1.745X-114.088. Then, the absolute content of FGL1 protein in each serum sample is substituted into the logistic regression equation to obtain the regression prediction probability p of each serum sample. The possible regression prediction probability p is used as the diagnostic point to calculate the sensitivity and specificity, and the ROC curve is drawn accordingly (e.g. Figure 1 As shown), AUC is 1, sensitivity is 1, and specificity is 1. The Weiden index is calculated according to the coordinates of the ROC curve = specificity + sensitivity - 1. The predicted probability p value corresponding to the maximum value of the Weiden index is the best cut-off value of 0.5 that can diagnose and distinguish healthy subjects VS eczema patients.

[0038] The area under the ROC curve (AUC) has been widely recognized as an inherent accuracy indicator for evaluating the authenticity of diagnostic tests. When AUC is 0.5, it has no diagnostic significance; when AUC is between 0.5 and 0.7, it indicates a low diagnostic accuracy; when AUC is between 0.7 and 0.9, it indicates a medium diagnostic accuracy; when AUC>0.9, it indicates a high diagnostic accuracy.

[0039] 3. Verify the accuracy of FGL1 protein in diagnosing eczema

[0040] In the validation set, the best cut-off value obtained above was used as the diagnostic threshold to predict the serum samples of eczema patients VS healthy subjects. The number of correctly predicted samples divided by the total number of samples was the accuracy of FGL1 protein in distinguishing eczema patients VS healthy subjects. The accuracy of FGL1 protein in distinguishing eczema patients VS healthy subjects was 87.10% (27 / 31). The sample distribution diagram is shown in the figure below. Figure 2 shown.

[0041] Example 2: Diagnosis of urticaria

[0042] 1. Experimental samples and reagents

[0043] Thirty-one healthy subjects (no overlap with the healthy subjects in Example 1) and 35 urticaria patients were collected.

[0044] Healthy subjects were normal people with healthy physical examinations, and urticaria patients were diagnosed according to the 2022 Chinese Urticaria Diagnosis and Treatment Guidelines.

[0045] The age, gender and body mass index of healthy subjects and urticaria patients were matched, and there was no significant difference. The subjects and patients were randomly divided into a training set sample (including 18 healthy subjects and 18 urticaria patients) and a validation set sample (including 13 healthy subjects and 17 urticaria patients)

[0046] Exclusion criteria:

[0047] ① Patients with other acute diseases or uncontrolled chronic diseases; ② Patients with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system; ③ Patients with mental illness and unable to cooperate; ④ Pregnant or lactating women, or those preparing for pregnancy; ⑤ Those who have participated in other clinical trials within the past month; ⑥ Those who are unwilling to accept this study.

[0048] Main experimental reagents:

[0049] The ELISA reagent for measuring FGL1 protein was purchased from RayBiotech., Inc.

[0050] 2. Experimental Methods

[0051] 1. Collection and storage of serum samples

[0052] Fasting peripheral blood was collected from healthy subjects and urticaria patients in the morning and placed in a test tube without anticoagulant. The blood was naturally coagulated for 30-60 minutes at room temperature. After the blood coagulated, it was centrifuged at 2000 rpm for 10 minutes. The upper clear serum liquid was carefully aspirated into a sterile lyophilized tube, labeled, and stored in a -80°C refrigerator for later use.

[0053] 2. ELISA determination of FGL1 protein content in serum

[0054] The content of FGL1 protein in each serum sample was determined strictly according to the ELISA reagent assay instructions.

[0055] 3. Data processing method

[0056] The ROC curve of FGL1 protein in the test set for distinguishing healthy subjects from urticaria patients was established, and the area under the curve (AUC) and 95% confidence interval were calculated. Logistic regression was used to establish a regression equation to generate a set of new variables logit[P]. After logit[P]=Ln [p / (1-p)] The predicted probability p was obtained by transformation, and the ROC curve analysis was performed on the new variable. In the validation set, the best cut-off value obtained by the ROC curve was used as the threshold to calculate the diagnostic accuracy of FGL1 protein for urticaria.

[0057] 3. Experimental Results

[0058] 1. Differences in serum levels of FGL1 protein in healthy subjects and urticaria patients

[0059] In the training set, there were significant differences in the levels of FGL1 protein in the serum of healthy subjects VS urticaria patients. The absolute content of FGL1 in the serum of urticaria patients was significantly increased. The measurement results are shown in Table 2.

[0060] Table 2

[0061] Group FGL1 content (ng / mL) Urticaria 263.07±197.32 Healthy subjects 28.66±13.56

[0062] 2. ROC curve of FGL1 protein diagnosis for distinguishing healthy subjects from urticaria patients

[0063] Taking the FGL1 protein content (X) in the training set samples as the independent variable and the group (i.e., healthy subjects and urticaria patients) as the dependent variable, a logistic regression was performed on the FGL1 protein content in the serum samples of urticaria patients and healthy subjects to obtain the logistic regression equation Ln [p / (1-p)] =0.095X-5.526. Then, the absolute content of FGL1 protein in each serum sample is substituted into the logistic regression equation to obtain the regression prediction probability p of each serum sample. The possible regression prediction probability p is used as the diagnostic point to calculate the sensitivity and specificity, and the ROC curve is drawn accordingly (e.g. Figure 3 The AUC was 0.9722, the sensitivity was 1, and the specificity was 0.8889. The Wieden index was calculated based on the coordinates of the ROC curve = specificity + sensitivity - 1. The predicted probability p value corresponding to the maximum value of the Wieden index was the optimal cut-off value of 0.6856 for distinguishing healthy subjects from urticaria patients.

[0064] The area under the ROC curve (AUC) has been widely recognized as an inherent accuracy indicator for evaluating the authenticity of diagnostic tests. When AUC is 0.5, it has no diagnostic significance; when AUC is between 0.5 and 0.7, it indicates a low diagnostic accuracy; when AUC is between 0.7 and 0.9, it indicates a medium diagnostic accuracy; when AUC>0.9, it indicates a high diagnostic accuracy.

[0065] 3. Verify the accuracy of FGL1 protein in diagnosing urticaria

[0066] In the validation set, the best cut-off value obtained above was used as the diagnostic threshold to predict the serum samples of urticaria patients VS healthy subjects. The number of correctly predicted samples divided by the total number of samples was the accuracy of FGL1 protein in distinguishing urticaria patients VS healthy subjects. The accuracy of FGL1 protein in distinguishing urticaria patients VS healthy subjects was 96.67% (29 / 30). The sample distribution diagram is shown in the figure. Figure 4 shown.

[0067] In summary, there is a significant difference in the FGL1 protein content in the serum of healthy subjects and patients with eczema and urticaria, and the FGL1 protein content in the serum of patients with eczema and urticaria is significantly higher than that of healthy subjects. Further diagnostic efficacy tests show that FGL1 protein can effectively diagnose and distinguish healthy subjects from eczema or diagnose and distinguish healthy subjects from urticaria patients, with a high diagnostic accuracy, and can be used to develop a kit for diagnosing eczema or urticaria to improve diagnostic objectivity.

[0068] The purpose of the above-mentioned embodiments is to specifically introduce the essential content of the present invention, but those skilled in the art should know that the protection scope of the present invention should not be limited to the specific embodiments.

Claims

1. Use of FGL1 protein in preparing a kit for diagnosing eczema or urticaria; wherein: The kit is a serum detection kit, which contains a detection reagent for FGL1 protein.